Renal transplantation outcome in selected recipients with IgA nephropathy as native disease: A bicentric study

Aziz, Amir Kamal; Mousson, Christiane; Berthoux, F; Ducloux, Didier; Chalopin, Jean-Marc

doi:10.12659/aot.883457

Cited by 10 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some investigators reported a more favorable graft survival in IgAN patients than in other transplant recipients (64, 65), but other authors found similar results in an IgAN group than in non-IgAN transplant patients (48, 50, 58, 66). In particular, during the first 5 years after transplantation allograft survival for primary IgAN patients seems to be better than that of recipients with other primary renal diseases (12, 46, 64, 66, 67).…”

Section: Patient and Renal Survival Of Kidney Transplant In Igan Patimentioning

confidence: 93%

Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation

et al. 2019

View full text Add to dashboard Cite

IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. The disease generally runs an indolent course but may lead to ESRD in 20–30% of patients in 20 years or more after diagnosis. Patients with IgA nephropathy are ideal candidates for renal transplant because they are generally relatively young and with few comorbidities. Their graft survival is better or comparable to that of controls at 10 years, though few data are available after 10 years of follow-up. Recurrence of the original disease in the graft is a well-known complication of transplant in IgAN and is a significant cause of deterioration of graft function. Recurrent IgAN rarely manifests clinically before 3 years post transplantation. Recurrence rate is estimated to be around 30% with considerable differences among different series. Despite these factors there is no certain recurrence predictor, young age at renal transplant, rapid progression of the original disease and higher levels of circulating galactose-deficient IgA1 and IgA-IgG immune complexes are all associated with a higher rate of recurrence. Which pathogenetic mechanisms are responsible for the progression of the recurrence to graft function deterioration, and what therapy can prevent or slow down the progression of the disease in the graft, are open questions. The aim of this review is to describe the clinical outcome of renal transplantation in IgA patients with attention to the rate and the predictors of recurrence and to discuss the available therapeutic options for the management of recurrence.

show abstract

Section: Patient and Renal Survival Of Kidney Transplant In Igan Patimentioning

confidence: 93%

Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Others have documented a 10 year graft survival in patients with recurrent IgAN that was similar when compared to that in other renal diseases (56). However, there is a significant amount of evidence showing that with even longer follow up, graft survival in patients with recurrence of IgAN might in fact be worse, ranging from 9.7%-13% graft loss after 10 years of follow up (37,57,58). A recent single center Italian study compared 190 transplanted IgAN patients to 380 non-diabetic control transplant recipients and demonstrated a 10% lower graft survival in the IgAN patients after 15 years of follow up (59).…”

Section: Epidemiology Of Recurrent Iganmentioning

confidence: 88%

Recurrent glomerular disease in the kidney allograft

Beck¹

2015

Front Biosci

View full text Add to dashboard Cite

“…For IgA nephropathy, there is an incremental increase over time in the risk of GN recurrence after kidney transplantation, with reported recurrence rates of between 10 and 30%. Even though the risk of recurrence-related allograft loss is not consistently reported in all studies, allograft loss has been reported in up to 1 in every 5-10 patients with IgA nephropathy recurrence [15][16][17][18][19][20][21]. For patients with kidney failure from primary FSGS, the risk of disease recurrence may be as high as 80%, with the majority occurring in the early posttransplant period [15,16,22,23].…”

Section: Epidemiology Of Glomerulonephritides Recurrence and Recurren...mentioning

confidence: 99%

Recurrent glomerulonephritis after kidney transplantation: a practical approach

Souza

Prunster

Chan

et al. 2021

Current Opinion in Organ Transplantation

View full text Add to dashboard Cite

Purpose of review This review will provide a practical approach in the assessment of kidney failure patients with primary glomerulonephritides (GN) being considered for kidney transplantation, focusing on high-risk subtypes of immunoglobulin A nephropathy, focal segmental glomerulosclerosis, idiopathic membranous glomerulonephritis and membranoproliferative glomerulonephritis. Recent findings Recurrent glomerulonephritis remains one of the most common causes of allograft loss in kidney transplant recipients. Although the epidemiology and clinical outcomes of glomerulonephritis recurrence occurring after kidney transplantation are relatively well-described, the natural course and optimal treatment strategies of recurrent disease in kidney allografts remain poorly defined. With a greater understanding of the pathophysiology and treatment responses of patients with glomerulonephritis affecting the native kidneys, these discoveries have laid the framework for the potential to improve the management of patients with high-risk glomerulonephritis subtypes being considered for kidney transplantation. Summary Advances in the understanding of the underlying immunopathogenesis of primary GN has the potential to offer novel therapeutic options for kidney patients who develop recurrent disease after kidney transplantation. To test the efficacy of novel treatment options in adequately powered clinical trials requires a more detailed understanding of the clinical and histological characteristics of kidney transplant recipients with recurrent glomerulonephritis.

show abstract

Renal transplantation outcome in selected recipients with IgA nephropathy as native disease: A bicentric study

Cited by 10 publications

References 0 publications

Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation

Immunoglobulin A Nephropathy. Recurrence After Renal Transplantation

Recurrent glomerular disease in the kidney allograft

Recurrent glomerulonephritis after kidney transplantation: a practical approach

Contact Info

Product

Resources

About